SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 197.62+0.1%Dec 24 12:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (13637)1/23/1998 1:56:00 AM
From: Andrew H  Read Replies (2) of 32384
 
>>Andy, I have not found the PFE story on Droloxifene linked to LGND by any of the wire services yet (PRNewswire and Reuters). I have to check out Dow Jones.<<

That's encouraging--maybe we should write jill and ask her to delete our posts from SI before anyone reads them. (:>)

The more I think about it, the more I think it benefits LGND. 3% royalty vs. 1%, and a FAR LARGER market for osteo prevention than for advanced breast cancer. Really, to the extent that droloxifene is a factor for LGND (a fairly small extent, IMO, except for milestones which will probably not be affected), this is clearly a plus for LGND when a little thought is applied to the situation.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext